The studies indicate that the DBT such as the combination treatment with anti-PD1 and anti-CTLA4 ICIs have significantly increased the objective response rates (ORRs) in melanoma (from 43.7% to 57.6%)9 and non-small cell lung cancer (NSCLC) (35.9%)10. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.